Treating Fibrosis with Nanomedicine: A Clinical Review of Anti-fibrotic Strategies for Liver and Lung Disease

Abstract

Fibrosis, a pathological scarring process in organs like the liver and lungs, remains a major cause of morbidity and mortality worldwide, with current therapies often limited by poor efficacy and significant side effects. The complex and multifactorial pathogenesis of fibrosis necessitates innovative therapeutic strategies that can precisely target underlying cellular and molecular mechanisms. This review critically examines the burgeoning role of nanomedicine in meeting this urgent clinical need by enabling targeted and efficient anti-fibrotic interventions. We explore the design and application of advanced nanocarrier platforms, including lipid nanoparticles, polymeric systems, and biomimetic vesicles, for enhanced drug delivery to fibrotic tissues. The review delves into how these nanoplatforms are engineered to target key pro-fibrotic pathways and cell types, such as hepatic stellate cells in liver fibrosis and M2 macrophages in pulmonary fibrosis. Further, we summarize promising preclinical applications of nanomedicine for both liver and lung diseases, highlighting significant reductions in collagen deposition and other fibrosis markers. The potential of natural compounds and herbal medicines, when formulated as nanomedicines, to provide synergistic anti-fibrotic effects is also discussed. Additionally, we present key case studies that demonstrate the superior therapeutic outcomes of targeted nanotherapies in animal models. Finally, the challenges and considerations in the clinical translation of these nanomedicine strategies are outlined. Looking forward, future progress in this field hinges on overcoming translational barriers such as scalable manufacturing and long-term biosafety profiles. The integration of diagnostic and therapeutic functions into single ‘theranostic’ nanoplatforms presents a promising direction for personalized medicine. Ultimately, the continued convergence of nanotechnology with a deepening understanding of fibrotic disease biology is poised to yield groundbreaking and effective anti-fibrotic therapies.